2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1701
    Morphiceptin 74135-04-9 99.07%
    Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for Enkephalin receptors.
    Morphiceptin
  • HY-P2824
    Streptokinase, β-hemolytic streptococcus (Lancefield Group C) 9002-01-1
    Streptokinase, β-hemolytic streptococcus (Lancefield Group C) is a bacteria-derived protein and a plasminogen activator. Streptokinase is widely used for the research of the blood-clotting disorders. Streptokinase improves reperfusion blood flow after coronary artery occlusion.
    Streptokinase, β-hemolytic streptococcus (Lancefield Group C)
  • HY-P3395
    Catestatin (human) 197151-46-5 98.62%
    Catestatin human, a catecholamine release-inhibitory peptide, is a pleiotropic peptide involved in cardiovascular protection with its antihypertensive and angiogenic effects. Catestatin human can be used in the study of inflammatory diseases .
    Catestatin (human)
  • HY-P9987
    Crizanlizumab 1690318-25-2
    Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
    Crizanlizumab
  • HY-101222
    SB-203186 hydrochloride 207572-69-8 99.94%
    SB-203186 hydrochloride is a potent, selective and competitive 5-HT4 antagonist. SB-203186 hydrochloride antagonizes the 5-HT4 receptor-mediated relaxations of the carbachol-contracted rat isolated oesophagus against 5-HT with pKB values of 10.9 (rat oesophagus), 9.5 (guinea-pig ileum), and 9.0 (human colon) respectively.
    SB-203186 hydrochloride
  • HY-101253
    AM-92016 hydrochloride 133229-11-5 99.28%
    AM-92016 hydrochloride is a specific blocker of rectifier potassium current (IK). AM-92016 hydrochloride delays rectifier potassium channel (IK), repolarizes the membrane thereby restricting the duration of the nerve impulse thereby restricting the duration of the nerve impulse.
    AM-92016 hydrochloride
  • HY-101423
    NIH-12848 959551-10-1 99.96%
    NIH-12848 is a putative phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) inhibitor with an IC50 of 1 μM.
    NIH-12848
  • HY-101701
    Hepronicate 7237-81-2 99.95%
    Hepronicate is a peripheral vasodilator with blood lipid lowering action.
    Hepronicate
  • HY-103214
    Bucindolol 71119-11-4 ≥99.0%
    Bucindolol is a β1-adrenergic receptor blocker, with intrinsic sympathomimetic activity, used in the research of heart failure.
    Bucindolol
  • HY-103335
    O1918 536697-79-7
    O1918 is a selective non-CB1 receptor and GPR18 antagonist.
    O1918
  • HY-108845
    Tenecteplase 191588-94-0
    Tenecteplase (TNK-tPA) is a modified tissue plasminogen activator. Tenecteplase is a recombinant human tissue plasminogen activator (rt-PA) that has been bioengineered to produce mutations in three gene loci. Tenecteplase (TNK-tPA) can be used in the study of acute ischemic stroke.
    Tenecteplase
  • HY-109897
    CV-6209 100488-87-7
    CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats.
    CV-6209
  • HY-111820
    CK1-IN-1 1784751-20-7 99.19%
    CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis.
    CK1-IN-1
  • HY-113042
    Prostaglandin B2 13367-85-6 ≥99.0%
    Prostaglandin B2 is a prostaglandin. Prostaglandin B2 is the main substance in cord blood mesenchymal stem cells, to inhibit DC-T Cell proliferation. Prostaglandin B2 also induces cutaneous vasoconstriction of the canine hind paw.
    Prostaglandin B2
  • HY-114794
    Desglymidodrine 3600-87-1
    Desglymidodrine (ST 1059), the active metabolite of Midodrine(HY-12749), is a selective α1-adrenoceptor agonist. Desglymidodrine is an effective arterial and venous vasoconstrictor and can be used to regulate blood pressure.
    Desglymidodrine
  • HY-116868
    Anecortave acetate 7753-60-8 99.81%
    Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases.
    Anecortave acetate
  • HY-117071
    Dabuzalgron 219311-44-1 98.72%
    Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function.
    Dabuzalgron
  • HY-123422
    GSK360A 931399-19-8 99.90%
    GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) .
    GSK360A
  • HY-124577
    MDI-2268 1609176-50-2 99.73%
    MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis.
    MDI-2268
  • HY-126562
    Piperlonguminine 5950-12-9 99.81%
    Piperlonguminine is an alkaloid amide isolated from the Piper species. Piperlonguminine shows various biological properties, including anti-inflammatory, antitumor, neuroprotective, anti-platelet, anti-melanogenic, antifungal and antibacterial activities.
    Piperlonguminine
Cat. No. Product Name / Synonyms Application Reactivity